Last reviewed · How we verify
Ropivacaine 0,5%
At a glance
| Generic name | Ropivacaine 0,5% |
|---|---|
| Sponsor | ibrahim cardiac hospital and research institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Frozen Shoulder Treatment with Intra-Articular Corticosteroid Injection and Suprascapular Nerve Block (NA)
- Enhanced Recovery After Urologic Surgery (NA)
- Regional Anesthesia Techniques in Breast Surgery (NA)
- Multimodal Analgesia Versus Peripheral Nerve Block for Postoperative Pain Management After Lower Limb Injury Surgery (NA)
- Efficacy and Safety of Liposomal Bupivacaine and Ropivacaine in Upper Limb Surgery (NA)
- AoA Guided Thoracic Epidural Analgesia for Abdominal Aortic Repair (NA)
- Difference in Occurrence of Rebound Pain in Patients Undergoing Surgery Under Popliteal Block or Ankle Block (NA)
- Comparison of Using CIBPB With or Without IV-PCA After Arthroscopic Rotator Cuff Repair (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0,5% CI brief — competitive landscape report
- Ropivacaine 0,5% updates RSS · CI watch RSS
- ibrahim cardiac hospital and research institute portfolio CI